Loading patent…
AssigneeVanderbilt University
InventorNancy J. Brown
Estimating the term…
Deficiencies in certain physiological pathways are linked with ACE or vasopeptidase inhibitor associated angioedema. Additionally, detection and/or measurement of dipeptidyl peptidase IV (DPP IV) enzyme activity and aminopeptidase P (APP) enzyme activity is a predictor of this risk. The present invention provides biological markers, diagnostic tests, and pharmaceutical indications that are useful in the diagnosis and treatment of angioedema and in the marketing and safety of certain medications. This ability can be important for the treatment of a subject that is in need of or are taking an angiotensin-converting enzyme (ACE) inhibitor and/or a vasopeptidase inhibitor (combined ACE and neutral endopeptidase (NEP) inhibitor), which are commonly used in the treatment of hypertension (high blood pressure), diabetes, and cardiac and renal diseases.
A method of identifying a subject that is susceptible to developing an angioedemic condition during a course of treatment comprising administering one of an ACE inhibitor and a vasopeptidase inhibitor, comprising:
A method of determining contraindication for administration of one of an ACE inhibitor and a vasopeptidase inhibitor to an individual, comprising:
Dependencies are inferred from the claim text.